ArticleFrontiers in oncology2026
Predicting recurrence of prostate cancer after radical treatment using AI models based on PET/CT radiomics: a dual-center study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Predicting prostate cancer (PCa) recurrence after radical treatment is crucial for personalised adjuvant therapy. This study aimed to compare different algorithms in order to select the best model for predicting recurrence. Therefore, a retrospective cohort analysis was conducted on 72 patients with radical prostate cancer, including 39 patients with biochemical recurrence and 33 patients without recurrence. We extracted features from imaging data, construct and evaluate 10 machine learning models and 8 deep learning models. Model performance was assessed using the area under the curve (AUC), accuracy, sensitivity, specificity, precision, 10-fold cross-validation AUC, and F1-score. In addition, the feature importance was analysed. Among all models, the MLP-Mixed-Act model exhibited superior performance in all evaluation indicators (AUC = 0.910, accuracy =0.819, sensitivity =0.744, specificity =0.909, precision =0.912, F1 = 0.817), thereby indicating its strong predictive ability and clinical application potential. This study provides a theoretical basis for the development of preventive and non-invasive recurrence prediction tools. Especially in the context of valuing the tumor microenvironment, accurate recurrence prediction can effectively help select immunotherapy strategies, improve treatment efficacy and prognosis, and support for personalized treatment of PCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.